Hepatitis C Therapy

Pilot trial results of triple therapy interferon drug for hepatitis C presented

Published in Hepatitis Weekly, July 18th, 2005

SciClone Pharmaceuticals, Inc. (SCLN) announced the poster presentation of additional data evaluating Zadaxin (thymosin alpha 1), in combination with pegylated interferon alpha and ribavirin, as a potential treatment for the hepatitis C virus (HCV) at the Congress of the Mexican Association of Hepatology annual conference.

Data reported in this presentation includes a full 72-week analysis of 30 HCV non-responder patients enrolled in this pilot trial and builds on the results reported on 25 of these patients in November 2004 at the American Association for the Study of Liver Disease (AASLD).

Of the 30 patients evaluated at week 72, at which point...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2005-07-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry